Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -5.06% | 150.00 | 0.0% | $678.53m | |
| AMGN | Amgen, Inc. | -0.35% | 249.70 | 1.5% | $585.90m | |
| GILD | Gilead Sciences, Inc. | -1.27% | 65.18 | 1.0% | $429.55m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.65% | 294.29 | 1.9% | $402.50m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.81% | 624.83 | 2.6% | $354.90m | |
| ILMN | Illumina, Inc. | -1.86% | 209.06 | 3.3% | $307.20m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 2.22% | 4.15 | 0.7% | $290.10m | |
| NVAX | Novavax, Inc. | -5.56% | 37.18 | 75.7% | $231.38m | |
| BIIB | Biogen, Inc. | -0.57% | 216.34 | 1.8% | $185.52m | |
| BNTX | BioNTech SE | -2.91% | 147.61 | 0.0% | $150.86m | |
| SAVA | Cassava Sciences, Inc. | 2.92% | 26.47 | 0.0% | $120.22m | |
| GOVX | GeoVax Labs, Inc. | -12.83% | 1.97 | 0.0% | $104.86m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -1.98% | 92.96 | 4.2% | $97.95m | |
| CRSP | CRISPR Therapeutics AG | 0.57% | 72.15 | 0.6% | $91.12m | |
| EXAS | EXACT Sciences Corp. | -2.73% | 38.48 | 17.6% | $84.05m |
Company Profile
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics & Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.